// App-Quantinova.ai

: Clinician and Patient Evaluation of Improvement for Eyebrow and Eyelashes Hair Loss During Baricitinib Phase 3 trials BRAVE-AA1 and BRAVE-AA2

Researchers

Presenter

  • Brett King

Principal Investigators

  • Manabu Ohyama

  • Arash Mostaghimi

  • Abraham Zlotogorski

  • Chiara Chiasserini

  • Amy M. DeLozier

  • Guanglei Yu

  • Sarah Stanley

  • Wen-Shuo Wu

  • Antonella Tosti

Medical Centers

  • Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT

  • Department of Neurosurgery, Kyorin University Faculty of Medicine, Tokyo, Japan

  • Department of Medicine, Brigham and Women's Hospital, Boston, MA

  • Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel

  • Eli Lilly and Company, Indianapolis, IN

  • Dermatology & Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, FL

Locations

  • Japan

  • United States

  • United Kingdom

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Janus kinase

Drug/Treatment

  • Baricitinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT03570749

  • NCT03899259

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved